CN105377301B - 高药物载量的丁丙诺啡微球和生产其的方法 - Google Patents

高药物载量的丁丙诺啡微球和生产其的方法 Download PDF

Info

Publication number
CN105377301B
CN105377301B CN201480021351.9A CN201480021351A CN105377301B CN 105377301 B CN105377301 B CN 105377301B CN 201480021351 A CN201480021351 A CN 201480021351A CN 105377301 B CN105377301 B CN 105377301B
Authority
CN
China
Prior art keywords
buprenorphine
phase
solvent
dispersed phase
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480021351.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377301A (zh
Inventor
T·里奇
B·C·萨努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CN105377301A publication Critical patent/CN105377301A/zh
Application granted granted Critical
Publication of CN105377301B publication Critical patent/CN105377301B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480021351.9A 2013-03-15 2014-03-14 高药物载量的丁丙诺啡微球和生产其的方法 Active CN105377301B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/837,181 US9393211B2 (en) 2013-03-15 2013-03-15 High drug load buprenorphine microspheres and method of producing same
US13/837,181 2013-03-15
PCT/US2014/027982 WO2014143839A1 (en) 2013-03-15 2014-03-14 High drug load buprenorphine microspheres and method of producing the same

Publications (2)

Publication Number Publication Date
CN105377301A CN105377301A (zh) 2016-03-02
CN105377301B true CN105377301B (zh) 2020-06-05

Family

ID=51528078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480021351.9A Active CN105377301B (zh) 2013-03-15 2014-03-14 高药物载量的丁丙诺啡微球和生产其的方法

Country Status (9)

Country Link
US (1) US9393211B2 (https=)
EP (1) EP2968577B1 (https=)
JP (1) JP6678571B2 (https=)
CN (1) CN105377301B (https=)
BR (1) BR112015022985A2 (https=)
CA (1) CA2904432A1 (https=)
ES (1) ES2717942T3 (https=)
MX (1) MX362709B (https=)
WO (1) WO2014143839A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
US9636308B2 (en) * 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3141241A1 (en) * 2015-09-08 2017-03-15 Andreas Voigt Sustained release low dose formulations and uses thereof
CN105596298B (zh) * 2015-12-18 2018-08-14 山东大学 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法
EP3419596A1 (en) * 2016-02-23 2019-01-02 BioDelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
TWI743193B (zh) 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
US12433841B2 (en) 2020-02-26 2025-10-07 Fordoz Pharma Corp. Injectable controlled-release formulations of progestogen drugs
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN114392384B (zh) * 2021-12-24 2023-04-11 河南驼人医疗器械研究院有限公司 一种制备高载药量栓塞微球的方法及收集装置
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途
CN120152701A (zh) * 2022-10-31 2025-06-13 奥克伍德实验室有限责任公司 包含奥曲肽的混合释放曲线聚合物微球制剂及其制备和使用方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368406B1 (en) * 1988-11-10 1993-07-28 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
WO2001015699A1 (en) * 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
EP1555023A2 (en) * 1999-08-27 2005-07-20 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
TW200836770A (en) * 2007-03-08 2008-09-16 Univ Kaohsiung Medical Controlled release system and manufacture method thereof
WO2011087496A1 (en) * 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
CN102137657A (zh) * 2008-08-29 2011-07-27 东国制药株式会社 通过溶剂交流蒸发法制备缓释微球的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US20100086597A1 (en) 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368406B1 (en) * 1988-11-10 1993-07-28 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
WO2001015699A1 (en) * 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
CN1382051A (zh) * 1999-08-27 2002-11-27 南方研究所 可注射的丁丙诺啡微粒组合物及其用途
EP1555023A2 (en) * 1999-08-27 2005-07-20 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
TW200836770A (en) * 2007-03-08 2008-09-16 Univ Kaohsiung Medical Controlled release system and manufacture method thereof
CN102137657A (zh) * 2008-08-29 2011-07-27 东国制药株式会社 通过溶剂交流蒸发法制备缓释微球的方法
WO2011087496A1 (en) * 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Preparation of microspheres by the solvent evaporation technique";Patrick BO"Donnell;《 Advanced Drug Delivery Reviews》;19991013;第28卷(第1期);第28页左栏倒数第1段 *

Also Published As

Publication number Publication date
MX2015012232A (es) 2015-12-01
CN105377301A (zh) 2016-03-02
US9393211B2 (en) 2016-07-19
ES2717942T3 (es) 2019-06-26
US20140271869A1 (en) 2014-09-18
MX362709B (es) 2019-02-05
EP2968577A1 (en) 2016-01-20
EP2968577A4 (en) 2016-11-23
BR112015022985A2 (pt) 2017-08-22
CA2904432A1 (en) 2014-09-18
JP6678571B2 (ja) 2020-04-08
WO2014143839A1 (en) 2014-09-18
JP2016513721A (ja) 2016-05-16
EP2968577B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CN105377301B (zh) 高药物载量的丁丙诺啡微球和生产其的方法
JP7038741B2 (ja) 放出制御が容易な徐放性薬物微粒子の製造方法
US9636308B2 (en) High drug load buprenorphine microspheres and method of producing same
JP2016513721A5 (https=)
CN115942935B (zh) 包括氯胺酮的微球制剂及其制备和使用方法
US11992559B2 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20250032451A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
US20240000772A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
CN116916893A (zh) 包含btk抑制剂的微球制剂及其制备和使用方法
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
WO2024163997A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant